LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

Kodu・Aktsiate loetelu・IQVIA Holdings Inc

IQVIA Holdings Inc

Avatud

SektorTervishoid

174.9 3.55

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

168.06

Max

175.41

Põhinäitajad
By Trading Economics
Sissetulek	-239M 275M
Müük	-213M 4.2B
P/E Sektori keskmine	21.559 51.415
Aktsiakasum	2.9
Kasumimarginaal	6.625
Töötajad	93,000
EBITDA	-245M 802M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.25% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	21. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	1.9B 29B
Eelmine avamishind	171.35
Eelmine sulgemishind	174.9

Uudiste sentiment

By Acuity

50%

162 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

150.68 / 153.45 Toetus ja vastupanu

IQVIA Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2026, 22:54 UTC

Tulu

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. mai 2026, 23:17 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. mai 2026, 23:16 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. mai 2026, 23:15 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. mai 2026, 23:14 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. mai 2026, 23:02 UTC

Market Talk

Tulu

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. mai 2026, 22:59 UTC

Market Talk

Tulu

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. mai 2026, 22:24 UTC

Tulu

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Revenue Growth 47%>XRO.AU

13. mai 2026, 22:22 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. mai 2026, 22:18 UTC

Tulu

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. mai 2026, 22:16 UTC

Tulu

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. mai 2026, 22:13 UTC

Tulu

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. mai 2026, 22:12 UTC

Tulu

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero Did Not Declare a Dividend>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. mai 2026, 22:09 UTC

Tulu

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. mai 2026, 22:00 UTC

Tulu

Cisco to Shed Jobs for All-In AI Push -- Update

13. mai 2026, 21:11 UTC

Tulu

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

IQVIA Holdings Inc Prognoos

Hinnasiht

By TipRanks

25.25% tõus

12 kuu keskmine prognoos

Keskmine 215.9 USD 25.25%

Kõrge 245 USD

Madal 185 USD

Põhineb 12 Wall Streeti analüütiku instrumendi IQVIA Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi IQVIA Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

150.68 / 153.45Toetus ja vastupanu

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

162 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.